Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials

About one‐tenth of patients with difficult‐to‐treat chronic rhinosinusitis with nasal polyps (CRSwNP) have comorbid non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease (NSAID‐ERD). Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)‐4/IL‐13 receptor component, is an approved add‐on treatment in severe CRSwNP. This post hoc analysis evaluated dupilumab efficacy and safety in patients with CRSwNP with/without NSAID‐ERD.

[1]  Andrew A. White,et al.  The Role of Aspirin Desensitization Followed by Oral Aspirin Therapy in Managing Patients with Aspirin-Exacerbated Respiratory Disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma, and Immunology. , 2020, The Journal of allergy and clinical immunology.

[2]  V. Backer,et al.  EUFOREA Expert Board Meeting on Uncontrolled Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Biologics: Definitions and Management. , 2020, The Journal of allergy and clinical immunology.

[3]  M. Tabor,et al.  Systematic review of outcomes for endoscopic sinus surgery and subsequent aspirin desensitization in aspirin-exacerbated respiratory disease , 2020, World journal of otorhinolaryngology - head and neck surgery.

[4]  B. Lambrecht,et al.  Adult chronic rhinosinusitis , 2020, Nature Reviews Disease Primers.

[5]  J. Hagan,et al.  Elevated Urine Leukotriene E4 Is Associated With Worse Objective Markers in Nasal Polyposis Patients , 2020, The Laryngoscope.

[6]  A. Ramsey,et al.  Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease , 2020, American journal of rhinology & allergy.

[7]  L. James,et al.  Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps , 2020, Drug design, development and therapy.

[8]  C. Mueller,et al.  Associations between the Quality of Life and Nasal Polyp Size in Patients Suffering from Chronic Rhinosinusitis without Nasal Polyps, with Nasal Polyps or Aspirin-Exacerbated Respiratory Disease , 2020, Journal of clinical medicine.

[9]  D. Hijnen,et al.  Acute arthritis and arthralgia as an adverse drug reaction to dupilumab , 2019, Clinical and experimental dermatology.

[10]  D. Wang,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps 2020. , 2020, Rhinology.

[11]  C. Hopkins,et al.  Biologics for chronic rhinosinusitis. , 2019, The Cochrane database of systematic reviews.

[12]  B. Kirkham,et al.  Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series , 2019, The British journal of dermatology.

[13]  G. Yancopoulos,et al.  Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. , 2019, Gastroenterology.

[14]  M. Fried,et al.  Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease. , 2019, The journal of allergy and clinical immunology. In practice.

[15]  C. Bachert,et al.  Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis , 2019, Allergy.

[16]  Andrew A. White,et al.  Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper , 2018, Allergy.

[17]  M. Kohanski,et al.  Biomarkers in Chronic Rhinosinusitis with Nasal Polyps. , 2018, Immunology and allergy clinics of North America.

[18]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[19]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[20]  A. Peters,et al.  Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. , 2017, The journal of allergy and clinical immunology. In practice.

[21]  N. Graham,et al.  Commonality of the IL-4/IL-13 pathway in atopic diseases , 2017, Expert review of clinical immunology.

[22]  J. Levy,et al.  Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin‐exacerbated respiratory disease? , 2016, The Laryngoscope.

[23]  J. Steinke,et al.  Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease. , 2016, Immunology and allergy clinics of North America.

[24]  R. Schleimer,et al.  Chronic Rhinosinusitis with Nasal Polyps. , 2016, The journal of allergy and clinical immunology. In practice.

[25]  J. Boyce,et al.  Aspirin-Exacerbated Respiratory Disease--New Prime Suspects. , 2016, The New England journal of medicine.

[26]  A. Peters,et al.  Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. , 2015, American journal of respiratory and critical care medicine.

[27]  Andrew A. White,et al.  Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. , 2015, The Journal of allergy and clinical immunology.

[28]  F. Alt,et al.  Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes , 2014, Proceedings of the National Academy of Sciences.

[29]  L. Macdonald,et al.  Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice , 2014, Proceedings of the National Academy of Sciences.

[30]  R. Simon,et al.  The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. , 2007, The Journal of allergy and clinical immunology.

[31]  E. Prokopakis,et al.  Assessing quality of life and burden of disease in chronic rhinosinusitis: a review , 2019, Rhinology Online.

[32]  G. Paludetti,et al.  Pathophysiology of Chronic Rhinosinusitis with Nasal Polyps , 2019, All Around the Nose.

[33]  Andrew A. White,et al.  Role of Group 2 Innate Lymphocytes in Aspirin-exacerbated Respiratory Disease Pathogenesis , 2018, American journal of rhinology & allergy.